Analytical Data
-
Gene name
CCNA2
- Application
-
Alternative Names
CCN1; CCNA; Cyclin-A2
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20248
-
Expression Region
E174-L432
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNA2, a member of the cyclin family, plays a crucial role in the regulation of the cell cycle, particularly during the transition from the G1 phase to the S phase. This protein regulates the activity of cyclin-dependent kinase 2 (CDK2), thereby influencing DNA replication and cell proliferation. Research has shown that alterations in the expression of CCNA2 are associated with various cancers, underscoring its potential as a biomarker for oncogenesis and a target for therapeutic interventions. Understanding the structural and functional properties of CCNA2 can provide insights into its role in cell cycle regulation and mechanisms of tumorigenesis. Recent studies have focused on the recombinant expression and purification of CCNA2 to facilitate in-depth analyses of its biochemical functions and interactions with CDKs and other regulatory proteins. By producing CCNA2 in a controlled laboratory environment, researchers aim to elucidate its structural characteristics through techniques such as X-ray crystallography and NMR spectroscopy. These studies are pivotal for revealing the molecular mechanisms by which CCNA2 contributes to cell cycle control and its implications in cancer biology. The ongoing research in this area not only enhances our understanding of CCNA2's role in normal cellular functions but also holds promise for developing targeted therapies to combat diseases characterized by dysregulated cell cycle progression.
